Hutchmed China to make several presentations at cancer research meeting
5th Apr 2024 11:54
(Sharecast News) - Hutchmed China announced the upcoming presentation of new and updated data from various studies featuring compounds it had discovered on Friday, at the American Association of Cancer Research (AACR) annual meeting from 5 to 10 April in San Diego, California.
Read moreHutchmed endometrial cancer treatment gets priority review in China
2nd Apr 2024 12:11
(Sharecast News) - Hutchmed China announced the acceptance and granting of priority review by the China National Medical Products Administration (NMPA) for a new drug application combining fruquintinib and sintilimab for the treatment of advanced endometrial cancer on Tuesday.
Read moreHutchmed cancer treatment indication accepted for review in China
28th Mar 2024 13:02
(Sharecast News) - Hutchmed China announced a significant milestone in its cancer treatment work on Thursday, with the supplemental new drug application (sNDA) for savolitinib had been accepted for review by the China National Medical Products Administration (NMPA).
Read moreHutchmed partner Inmagene exercises options over two drug candidates
2nd Feb 2024 09:42
(Sharecast News) - Hutchmed China announced on Friday that Inmagene Biopharmaceuticals has exercised options to licence two drug candidates, IMG-007 and IMG-004, as part of their strategic partnership.
Read moreHutchmed's 'Elunate' approved under new Hong Kong rules
30th Jan 2024 10:32
(Sharecast News) - Hutchmed China announced the approval of its drug 'Elunate', or fruquintinib, by the Pharmacy and Poisons Board of Hong Kong on Tuesday, for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC).
Read moreHutchmed application for thrombocytopenia treatment accepted in China
11th Jan 2024 11:11
(Sharecast News) - Hutchmed China announced on Thursday that the new drug application (NDA) for sovleplenib, an oral inhibitor targeting spleen tyrosine kinase (Syk), had been accepted for review and granted priority review by China's National Medical Products Administration (NMPA).
Read moreHutchmed completes trial enrolment, keeps drugs on China funding list
13th Dec 2023 12:20
(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.
Read moreHutchmed completes trial enrolment, keeps drugs on China funding list
13th Dec 2023 12:20
(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.
Read moreHutchmed confirms new drug application for fruquintinib in Japan
29th Sep 2023 10:57
(Sharecast News) - Hutchmed China announced on Friday that its partner Takeda has officially submitted a new drug application (NDA) for fruquintinib to the Ministry of Health, Labour and Welfare (MHLW) in Japan.
Read moreDirector dealings: IPF non-exec picks up shares, Hutchmed China director linked to sale
14th Sep 2023 13:09
(Sharecast News) - International Personal Finance was among the companies on the list of director purchases on Thursday after a non-executive director spent more than £18k on shares.
Read moreHutchmed reports progress on two oncology fronts
12th Sep 2023 11:26
(Sharecast News) - Hutchmed China reported significant strides in oncology research on Tuesday, completing patient enrollment for a bridging study of tazemetostat, and announcing pivotal results for the phase 3b clinical trial of savolitinib.
Read moreHutchmed tumour therapy candidate gets breakthrough designation
29th Aug 2023 13:38
(Sharecast News) - Pharmaceuticals developer Hutchmed China announced on Tuesday that the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) has granted breakthrough therapy designation (BTD) to its investigational drug savolitinib.
Read moreHutchmed meets all endpoints in platelet disorder treatment trial
21st Aug 2023 08:24
(Sharecast News) - Hutchmed China reported a breakthrough from its recent phase three trial in sovleplenib on Monday, reporting that it met its primary endpoint and all secondary endpoints for treating adult patients with primary immune thrombocytopenia - a platelet disorder - (ITP) in China.
Read moreHutchmed launches new phase one study in China
10th Jul 2023 12:58
(Sharecast News) - Biopharmaceutical company Hutchmed China announced the launch of a phase one study in China for HMPL-415 on Monday - an investigational selective allosteric inhibitor that targeted Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2).
Read moreHutchmed China's colorectal cancer study to be published
16th Jun 2023 08:44
(Sharecast News) - Hutchmed China, alongside its partner Takeda, announced the publication of the phase three 'FRESCO-2' study results evaluating the use of fruquintinib in patients with previously-treated metastatic colorectal cancer (CRC) on Friday, in the Lancet medical journal.
Read more